← Leaderboards
Bryan Paul Schneider
Indiana University Indianapolis
$1,500,312
Attributed
$2,556,931
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $535.4K · FY2008–23$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,556,931 · 4
By mechanism
R01$2,546,993 · 2
M01$9,938 · 2
Top collaborators
- Xiongbin Lu3 shared
- Xinna Zhang3 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Xiongbin Lu$8,023,409
- Xinna Zhang$3,467,211
- Loren J Field$21,917,203
- David R. Jones$315,970
Others in their field
Top investigators on “Toxic Effect”
- George R Seage · Abt Associates, Inc.$224,114,540
- Peter C Adamson · National Childhood Cancer Foundation$126,756,857
- Gregory H Reaman · National Childhood Cancer Foundation$123,836,183
- Carol Nesel · Westat$116,355,411
- Mary M Horowitz · Medical College Of Wisconsin$90,165,506
- Barney Sparrow · Battelle Memorial Institute$88,494,220
Research focus
Toxic EffectTumorPharmaceutical PreparationsTrastuzumabBioinformaticsPaclitaxelResearch PersonnelMalignant Breast NeoplasmErbb2 GeneHormone TherapySourceGrantFundingGenesAnti-Pd-L1 TherapyAntineoplastic AgentsCancer BiologyAntigen PresentationAntibody-Drug ConjugatesCancer GenomicsClinical ApplicationBreast Cancer CellBrca MutationsAntibodies
Grant awards (8)
Targeting HER2-low breast cancer with 17p loss$524,740
R01 · FY2023 · CA
Targeting HER2-low breast cancer with 17p loss$524,740
R01 · FY2022 · CA
Targeting HER2-low breast cancer with 17p loss$535,448
R01 · FY2021 · CA
VEGF Gene Amplification/Haplotype as Biomarkers for Bevacizumab in Breast Cancer$303,371
R01 · FY2013 · CA · contact PI
VEGF Gene Amplification/Haplotype as Biomarkers for Bevacizumab in Breast Cancer$322,642
R01 · FY2012 · CA · contact PI
VEGF Gene Amplification/Haplotype as Biomarkers for Bevacizumab in Breast Cancer$336,052
R01 · FY2011 · CA · contact PI
PILOT EVALUATION OF THE ROLE OF POLYMORPHISMS OF ANGIOGENESIS GENES IN BREAST$9,734
M01 · FY2008 · RR · contact PI
CYTOCHROME P450 PHARMACOGENETICS AS A PREDICTOR OF TOXICITY AND CLINICAL EFFICAC$204
M01 · FY2008 · RR · contact PI